Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

BACKGROUND: Rash is one of the most common severe adverse events associated with use of vemurafenib for the treatment of melanoma, either as monotherapy or in combination with cobimetinib. The study aimed to identify pre-treatment patient characteristics predictive of developing severe rash with vem...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Hopkins, Ashley M., Rathod, Akash D., Rowland, Andrew, Kichenadasse, Ganessan, Sorich, Michael J.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7045585/
https://ncbi.nlm.nih.gov/pubmed/32103736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-6659-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars